Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sarcoma: early-phase trial registry
58 of 129 indexed Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #92 of 28,707 conditions by registered trial count.
129 US clinical trials · 58 currently recruiting · #92 of 28,707 conditions by registered trial count
Sarcoma: 129 US clinical trials tracked, 58 recruiting.
Sarcoma is the subject of 129 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 26 of these trials.
Enrollment posture brief
Registry condition sarcoma
OPEN 58 | RECR 45% | LATE 10 | EARLY 80 | RANK #92 | SPON 26
Volume-matched condition peers
Nearest open-share peer: Cancer (45% recruiting · 621 trials)
Sarcoma lists 58 open slots (45% of 129 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sarcoma is recruiting above its size-band peers.
58 of 129 indexed trials (45%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Sarcoma research.
Memorial Sloan Kettering Cancer Center accounts for 26 of 129 trials (20.2%). 72 distinct sponsors appear on at least one study for this condition label.
-
Most Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 123 trials that report a genuine target (sentinel values excluded). 80 of those (65%) plan for fewer than 100 participants.
-
Sarcoma research is mostly interventional.
106 interventional and 23 observational studies make up this index (82.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
129 total, page 3 of 3
S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone
SWOG Cancer Research Network
NCT00096213
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
NCT00474994
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Children's Oncology Group
NCT00066365
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
NCT00304083
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Mohammed M Milhem
NCT01106872
Safety and Efficacy Study Using Rexin-G for Sarcoma
Epeius Biotechnologies
NCT00505713
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
NCT00004250
Bevacizumab in Treating Patients With Angiosarcoma
Northwestern University
NCT00288015
A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
National Cancer Institute (NCI)
NCT00001573
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
National Cancer Institute (NCI)
NCT00001577
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
NCT04076579
Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications
Memorial Sloan Kettering Cancer Center
NCT02833246
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
NCT00006246
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Cancer Institute (NCI)
NCT02107963
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
University of Chicago
NCT00005066
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT01916135
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Children's Oncology Group
NCT00470275
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT01492673
T2* MRI Analysis for Sarcoma
Bryan Allen
NCT03658343
A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment
St. Jude Children's Research Hospital
NCT02041689
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
UNC Lineberger Comprehensive Cancer Center
NCT03076333
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma
Radiation Therapy Oncology Group
NCT00023725
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
NCT00003308
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
Memorial Sloan Kettering Cancer Center
NCT00027716
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
Gynecologic Oncology Group
NCT00101127
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
NYU Langone Health
NCT00003334
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
Roswell Park Cancer Institute
NCT00002985
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 43 |
| Phase 3 | 8 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sarcoma page
129 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Sarcoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoma condition card totals 129 registered trials; most-linked intervention filgrastim; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.